Zydus mirabegron tablets recalled for N-nitroso impurity
Zydus Pharmaceuticals is recalling one lot of Mirabegron Extended-Release 25 mg tablets due to higher-than-acceptable levels of N-Nitroso Mirabegron impurity. This impurity can potentially increase long-term health risks with continued use. No injuries have been reported.
From the FDA notice · Read the official notice ↗ · All Zydus recalls
What to do
- Check if your Mirabegron bottle has lot number E408618 (expiration 11/30/2026).
- Contact your pharmacy or doctor if you have this lot — do not stop taking the medication without guidance.
- Your pharmacy can provide an unaffected replacement or alternative medication.
Is yours affected?
Compare your label or packaging with the recalled product.
- Product
- Mirabegron Extended-Release Tablets, 25 mg, 30-count bottle, Rx only, Manufactured by: Zydus Lifesciences Ltd., Matoda, Ahmedabad, India, Distributed by: Zydus Pharmaceuticals (USA) Inc., Pennington, NJ 08534, NDC 70710-1159-3.
- Sold in
- Nationwide
- Made for
- Adults (0 months and older)
Details
- Illnesses reported
- None reported
- Manufactured in
- 73 Route 31 N, Pennington, NJ, United States
- Classification
- Class II
- Recall number
- D-0745-2026
In the FDA's words
- Description
- Mirabegron Extended-Release Tablets, 25 mg, 30-count bottle, Rx only, Manufactured by: Zydus Lifesciences Ltd., Matoda, Ahmedabad, India, Distributed by: Zydus Pharmaceuticals (USA) Inc., Pennington, NJ 08534, NDC 70710-1159-3. CGMP: Due to Out of Specification (OOS) result for N-Nitroso Mirabegron impurity. Lot # E408618, Expiry: 11/30/2026, NDC #: 70710-1159-3 Distribution: Nationwide in the USA
- Hazard
- CGMP: Due to Out of Specification (OOS) result for N-Nitroso Mirabegron impurity.